Virus-specific T cells for stubborn viral infections after transplant
Part of Infections clinical trials.
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 1 to 25 years old
- You had a stem cell transplant from a donor and it's been at least 21 days
- You have a viral infection (CMV, EBV, or BKV) that is not getting better with standard treatment
- Your white blood cell count (neutrophils) has recovered to a stable level after transplant
- You are on a low dose of steroids (or no steroids) – less than 0.5 mg/kg/day of prednisolone
- You do not have active graft-versus-host disease (GvHD) of grade 2 or higher
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special T-cell treatment (LB-DTK-MV) for people with virus infections (CMV, BKV, EBV) that did not get better with standard medicines. It is for patients who had a stem cell transplant or certain cancer therapies like CAR-T or bispecific antibodies.
This Phase 3 trial tests giving special immune cells from your stem-cell donor to treat difficult-to-control viral infections after a stem cell transplant. It may help your body fight the virus when standard antiviral medicines haven’t worked well enough.
This trial tests a new cell therapy (LB-DTK-BKV) for patients who developed a painful BK virus bladder infection after receiving a stem cell transplant and didn't improve with standard treatment. The therapy may help control the virus and reduce bleeding and pain.
This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.
This Phase 1 study tests an “off-the-shelf” type of immune cell therapy made to attack several viruses (EBV, CMV, adenovirus, and BK, and possibly JC) in people who had an allogeneic stem cell transplant and still have ongoing viral infection. It may help your body control the virus when standard treatments have not worked or you cannot tolerate them.
This trial tests a treatment using specially trained immune cells (virus-specific T-cells) to fight stubborn infections with adenovirus, CMV, or EBV in people with weakened immune systems, such as after a stem cell or organ transplant.
Hear when a new BKV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.